There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.
Find me on:

Recent Posts

Europe’s AI laws will cost companies a small fortune – but the payoff is trust

Posted by Healx on Feb 8, 2022 11:13:00 AM
By Dr Tim Guilliams, Co-Founder and CEO of Healx
Artificial intelligence isn’t tomorrow’s technology — it’s already here. Now too is the legislation proposing to regulate it.
Earlier this year, the European Union outlined its proposed artificial intelligence legislation and gathered feedback from hundreds of companies and organizations. The European Commission closed the consultation period in August, and next comes further debate in the European Parliament.
Read More

Topics: AI, Digital Health

Choosing to challenge: why diversity and inclusion is critical for business success

Posted by Healx on Feb 2, 2022 10:00:09 AM
As a mission-driven company, working to find treatments for people who are often excluded from the traditional drug discovery process, inclusion is at the very heart of what we do and why we do it. It’s also a key part of how we do it – by proactively partnering with rare disease patient groups and communities to ensure their voice, expertise and insight are at the heart of our efforts to find treatments. 
Read More

Topics: Diversity & Inclusion